ES8401492A1 - Procedimiento para la preparacion de derivados de cefem. - Google Patents

Procedimiento para la preparacion de derivados de cefem.

Info

Publication number
ES8401492A1
ES8401492A1 ES520226A ES520226A ES8401492A1 ES 8401492 A1 ES8401492 A1 ES 8401492A1 ES 520226 A ES520226 A ES 520226A ES 520226 A ES520226 A ES 520226A ES 8401492 A1 ES8401492 A1 ES 8401492A1
Authority
ES
Spain
Prior art keywords
preparation
cephalosporin derivatives
compounds
bacterial infections
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES520226A
Other languages
English (en)
Other versions
ES520226A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES520226A0 publication Critical patent/ES520226A0/es
Publication of ES8401492A1 publication Critical patent/ES8401492A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rigid Pipes And Flexible Pipes (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE CEFEM.SE HACE REACCIONAR EL COMPUESTO (II) CON PIRIDINA O UN DERIVADO DEL MISMO, DESPUES DE LO CUAL, EN CASO DE QUE LOS RADICALES R3 Y R6 SEAN GRUPOS FACILMENTE ELIMINABLES, ESTOS SON EFECTIVAMENTE ELIMINADOS POR TRATAMIENTO CON UN AGENTE PARA HIDROLISIS ACIDA, HIDROGENOLISIS O CON TIOUREA. SE OBTIENEN LOS COMPUESTOS (I) Y/O SUS SALES DE ADICION, FARMACEUTICAMENTE ACEPTABLES. EL INTERCAMBIO NUCLEOFILO DEL SUSTITUYENTE R3 SE EFECTUA EN PRESENCIA DE IONES DE SALES NEUTRAS TALES COMO IONES YODURO O TIOCIANATO.
ES520226A 1982-03-04 1983-03-02 Procedimiento para la preparacion de derivados de cefem. Expired ES8401492A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823207840 DE3207840A1 (de) 1982-03-04 1982-03-04 "cephalosporinderivate und verfahren zu ihrer herstellung"

Publications (2)

Publication Number Publication Date
ES520226A0 ES520226A0 (es) 1983-12-01
ES8401492A1 true ES8401492A1 (es) 1983-12-01

Family

ID=6157330

Family Applications (1)

Application Number Title Priority Date Filing Date
ES520226A Expired ES8401492A1 (es) 1982-03-04 1983-03-02 Procedimiento para la preparacion de derivados de cefem.

Country Status (21)

Country Link
US (1) US4647556A (es)
EP (1) EP0088320B1 (es)
JP (1) JPS58162592A (es)
KR (1) KR840004117A (es)
AT (1) ATE39696T1 (es)
AU (1) AU565927B2 (es)
CA (1) CA1219857A (es)
DE (2) DE3207840A1 (es)
DK (1) DK108183A (es)
ES (1) ES8401492A1 (es)
FI (1) FI830704L (es)
GR (1) GR77915B (es)
HU (1) HU190442B (es)
IL (1) IL68026A0 (es)
MA (1) MA19736A1 (es)
MT (1) MTP925B (es)
NO (1) NO830729L (es)
NZ (1) NZ203436A (es)
OA (1) OA07335A (es)
PT (1) PT76336B (es)
ZA (1) ZA831452B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66726A0 (en) * 1981-09-08 1982-12-31 Lilly Co Eli Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives
US4690921A (en) * 1983-10-11 1987-09-01 Yamanouchi Pharmaceutical Co., Ltd. Cephalosporin compounds and salts thereof
GB2148289B (en) * 1983-10-17 1987-09-23 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
JPS6094984A (ja) * 1983-10-28 1985-05-28 Dai Ichi Seiyaku Co Ltd セフエム誘導体
DE150507T1 (de) * 1983-12-29 1987-02-26 Mochida Pharmaceutical Co., Ltd., Tokio/Tokyo Cephalosporinverbindungen, verfahren zu ihrer herstellung und pharmazeutishe praeparate.
JPS60142987A (ja) * 1983-12-29 1985-07-29 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体
EP0148004A3 (en) * 1983-12-30 1986-04-23 Glaxo Group Limited Cephalosporin antibiotics
EP0150609A3 (en) * 1983-12-30 1986-04-23 Glaxo Group Limited Cephalosporin antibiotics
JPS60169486A (ja) * 1984-02-10 1985-09-02 Yamanouchi Pharmaceut Co Ltd 7−アミノ−3−置換メチル−3−セフエム−4−カルボン酸およびその低級アルキルシリル誘導体の製造法
DE3404906A1 (de) * 1984-02-11 1985-08-14 Bayer Ag, 5090 Leverkusen 1-oxadethiacephalosporinderivate sowie verfahren zu ihrer herstellung
JPS60222490A (ja) * 1984-04-17 1985-11-07 Dai Ichi Seiyaku Co Ltd セフアロスポリン誘導体およびその塩
EP0160546A3 (en) * 1984-04-26 1986-12-17 Yamanouchi Pharmaceutical Co. Ltd. Cephalosporin compounds, and their production, and medicaments containing them
EP0182633A3 (en) * 1984-11-20 1987-09-02 Ici Pharma Cephalosporin derivatives
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
GB8626245D0 (en) * 1985-11-27 1986-12-03 Ici Pharma Cephalosporin compounds
US5147871A (en) * 1986-07-03 1992-09-15 Hoffmann La-Roche, Inc. Anti-bacterial cephalosporin compounds
JPS63132893A (ja) * 1986-11-25 1988-06-04 Mochida Pharmaceut Co Ltd 新規セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
US4880798A (en) * 1986-11-25 1989-11-14 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
US5162523A (en) * 1989-07-21 1992-11-10 Hoffmann-La Roche Inc. Cephalosporin antibacterial compounds
US5159077A (en) * 1989-07-21 1992-10-27 Hoffmann-La Roche Inc. Penam antibacterial compounds
ATE341554T1 (de) * 1996-04-04 2006-10-15 Shionogi & Co Cephemverbindungen und medikamente die diese verbindungen enthalten
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
AU2009310959B2 (en) 2008-10-31 2015-05-07 Shionogi & Co., Ltd. Cephalosporin having catechol group
MX2012011521A (es) 2010-04-05 2013-03-08 Shionogi & Co Compuestos cefem que tienen un grupo catecol.
WO2011136268A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体
MX352760B (es) 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
WO2013051597A1 (ja) * 2011-10-04 2013-04-11 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
MX2020004205A (es) 2013-03-15 2021-11-16 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano.
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4970990A (es) * 1973-09-29 1974-07-09
US4298606A (en) * 1974-12-19 1981-11-03 Takeda Chemical Industries, Ltd. Thiazolylacetamido compounds
JPS5919553B2 (ja) * 1976-01-01 1984-05-07 武田薬品工業株式会社 セフアロスポリン
US4440766A (en) * 1976-03-09 1984-04-03 Fujisawa Pharmaceutical Co., Ltd. 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds
GB1591439A (en) * 1976-10-01 1981-06-24 Glaxo Operations Ltd 7-syn (oxyimino -acylamido) cephalosporins
AR228726A1 (es) * 1978-05-26 1983-04-15 Glaxo Group Ltd Procedimiento para la preparacion del antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)acetamido)-3-(1-piridiniometil)cef-3-em-4-carboxilato
GB2058791B (en) * 1978-05-26 1982-11-24 Glaxo Group Ltd Cephalosporin antibiotics
US4237168A (en) * 1979-06-11 1980-12-02 The Dow Chemical Company N-(4-Chloro-2-methylphenyl)-N-hydroxy methanimidamide and its pesticidal use
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS56131592A (en) * 1980-03-18 1981-10-15 Bristol Mayers Kenkyusho Kk Antimicrobial agent
ZA813787B (en) * 1980-06-18 1982-07-28 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
FR2485540A1 (fr) * 1980-06-30 1981-12-31 Sanofi Sa Nouveaux derives antibiotiques des cephalosporines, leur procede de preparation et les medicaments en contenant
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4396619A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin betaines
US4396620A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin quinolinium betaines
ZA826538B (en) * 1981-09-08 1984-04-25 Lilly Co Eli Thieno and furopyridinium-substituted cephalosporin derivatives
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4501739A (en) * 1982-01-19 1985-02-26 Eli Lilly And Company Thieno and furopyridinium-substituted cephalosporins

Also Published As

Publication number Publication date
IL68026A0 (en) 1983-06-15
HU190442B (en) 1986-09-29
NZ203436A (en) 1986-06-11
KR840004117A (ko) 1984-10-06
NO830729L (no) 1983-09-05
ES520226A0 (es) 1983-12-01
ZA831452B (en) 1983-11-30
MTP925B (en) 1984-02-13
EP0088320A3 (en) 1986-03-19
MA19736A1 (fr) 1983-10-01
ATE39696T1 (de) 1989-01-15
DK108183A (da) 1983-09-05
AU565927B2 (en) 1987-10-01
JPS58162592A (ja) 1983-09-27
OA07335A (fr) 1984-08-31
EP0088320A2 (de) 1983-09-14
FI830704A0 (fi) 1983-03-02
PT76336B (de) 1985-12-13
CA1219857A (en) 1987-03-31
EP0088320B1 (de) 1989-01-04
PT76336A (de) 1983-04-01
GR77915B (es) 1984-09-25
DE3378827D1 (en) 1989-02-09
FI830704L (fi) 1983-09-05
DE3207840A1 (de) 1983-09-15
DK108183D0 (da) 1983-03-03
AU1203983A (en) 1983-09-08
US4647556A (en) 1987-03-03

Similar Documents

Publication Publication Date Title
ES8401492A1 (es) Procedimiento para la preparacion de derivados de cefem.
ES8304143A1 (es) "procedimiento para la preparacion de derivados de cefem".
ES8201168A1 (es) Procedimiento para la preparacion de derivados de cefalospo-rina
ES8603497A1 (es) Procedimiento para preparar derivados de cefalosporina
ES8407495A1 (es) Procedimiento para preparar sales por adicion de acidos de compuestos de cefem cristalizados
HUT49614A (en) Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds
HUT42492A (en) Process for producing cepheme-carboxylic acid derivatives and pharmaceutical compositions containing them as active agents